Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists

被引：0
|
作者：
Scott Cohen
Hillel Sternlicht
George L. Bakris
机构：
[1] George Washington University,Department of Medicine
[2] Washington DC VA Medical Center,Department of Medicine, Section of Nephrology
[3] Georgetown University Medicine,Department of Medicine Section of Endocrinology
[4] Diabetes and Metabolism University of Chicago Medicine,undefined
来源：
Current Diabetes Reports | 2022年 / 22卷
关键词：
Aldosterone; Inflammation; Kidney; Cardiovascular; Nonsteroidal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：213 / 218
页数：5
相关论文
共 50 条
  • [1] Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Cohen, Scott
    Sternlicht, Hillel
    Bakris, George L.
    [J]. CURRENT DIABETES REPORTS, 2022, 22 (05) : 213 - 218
  • [2] A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients
    Spasovski, Goce
    Rroji, Merita
    Hristov, Goce
    Bushljetikj, Oliver
    Spahia, Nereida
    Bushletikj, Irena Rambabova
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (03) : 170 - 178
  • [3] Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Li, Jiahua
    Albajrami, Oltjon
    Zhuo, Min
    Hawley, Chelsea E.
    Paik, Julie M.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (11): : 1678 - 1688
  • [4] Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Winiarska, Agata
    Knysak, Monika
    Nabrdalik, Katarzyna
    Gumprecht, Janusz
    Stompor, Tomasz
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [5] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [6] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [7] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [8] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    [J]. LANCET, 2021, 398 (10296): : 262 - 276
  • [9] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [10] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
12345